Grace Lytle OD, MS Joins Avellino Labs as Senior Medical Director
Genetic Test for Refractive Surgery Safety has Screened More Than a Half-Million Patients for Corneal Dystrophy with More Than 500 Positive Results
16 Nov, 2015, 10:21 ET
MENLO PARK, Calif., Nov. 16, 2015 /CNW/ -- Avellino Lab USA, developer of the first genetic test for corneal dystrophy, today announced that Grace Lytle OD, MS has joined the company as Senior Medical Director. Currently focused on commercialization, the company has tested more than 500,000 patients for inherited corneal dystrophy with its DNA safety test to date and protected over 500 positive patients from complications and loss of vision.
"Grace has played a pivotal role in leading clinical studies and coordinating physician education to establish new ophthalmic technology and clinical practices among US and international cornea specialists. This experience directly correlates with the challenge in front of Avellino Labs. Grace will play a key role in our efforts to focus on evidence based education in building a foundation for our global business," commented Peter Falzon, CEO of Avellino Lab USA.
Grace distinguished herself at the New England College of Optometry by graduating first in her doctoral class, and continued on with post-graduate research and numerous publications. After completing advanced residency training in cornea and contact lens at the New England Eye Institute, Grace worked as an optometrist in clinical practice for several years before entering industry as a director and vice president of professional education.
About Avellino Lab USA
Avellino Lab is currently the industry leader in LASIK and refractive surgery safety testing, offering the first and only commercially available test for corneal dystrophy. Refractive surgery is known to exacerbate corneal dystrophy, causing vision loss and blindness in refractive surgery patients whose corneal dystrophy may not be detectable without the Avellino DNA Test. By screening for corneal dystrophy prior to refractive surgery, patients who test negative for the mutations can move forward with the surgery with confidence. The current test was first introduced to the U.S. market in April 2014 and is now available in 50 countries.
To learn more please visit http://www.avellinolab.com/us/.
Scott Korney, COO
Logo - http://photos.prnewswire.com/prnh/20130514/SF12152LOGO
SOURCE Avellino Labs
Share this article